Navigation Links
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
Date:11/10/2008

lular carcinoma, soft tissue sarcoma, GIST tumors, mesothelioma, and carcinoma of the appendix. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Disease stabilization, defined as time on treatment without progression for at least 6 months has been seen in 20 tumor types, including metastatic renal cell cancer, hepatocellular carcinoma, melanoma, carcinoid, prostate, head and neck, breast, and small cell lung cancer. Responding patients, including stable disease, have been treated for various durations up to more than three years.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
6. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
7. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
8. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
9. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
10. Lippincott Williams & Wilkins Selected as Publisher of the Journal of Neuroscience Nursing
11. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aspen Advisors, a U.S.-based healthcare consulting firm, announced today that ... Best Places to Work in Healthcare for 2014. ... creating workplaces that enable employees to perform at their optimum ... an employee engagement and satisfaction survey. This is the ... a “Best Places to Work in Healthcare”. , "We are ...
(Date:8/21/2014)... Absence seizures are believed to be elicited by ... of the brain that regulate influxes of calcium. ... generate burst firing, leading the neurons to enter ... the relationship between burst firing and absence seizures, ... seizures in mice using gene targeting techniques to ...
(Date:8/21/2014)... According to researchers at the University of Montreal, the ... important role as we train our bodies, movements and, ... sleep. While researchers knew that sleep helped us the ... known why. "The subcortical regions are important in information ... When consolidation level is measured after a period of ...
(Date:8/21/2014)... August 21, 2014 Bedros Keuilian’s Annual Fitness ... the industry, attended by many people already earning seven-figure incomes. ... is usually only open to the owners of Keuilian’s ... , This year’s Fit Body Boot Camp World Conference will ... a fitness boot camp or are struggling with ...
(Date:8/21/2014)... Minn. (PRWEB) August 21, 2014 ... social wellness solutions, announced today that it has entered ... medical best practices, mobile technology and predictive analytics for ... communities. , According to Michael Emerson , ... applied for two patents on the technology used in ...
Breaking Medicine News(10 mins):Health News:Modern Healthcare Names Aspen Advisors Among the Top 100 Employers in the Healthcare Industry for a Fourth Consecutive Year 2Health News:Learning to play the piano? Sleep on it! 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3Health News:Hunhu Healthcare Enters into Licensing Agreement with Mayo Clinic 2
... Cancers and Colorectal Screening Among Key ProvisionsBETHESDA, Md., ... and its more than 10,000 physician members congratulate ... today for the introduction of "21st Century Cancer ... Treatment) Act" and their vow to renew the ...
... The ,Help is Here Express, bus tour will be ... 3 at various cities throughout the state in order ... programs that provide prescription medicines for free or nearly ... exceeding that of the nation (8.1 percent), the Partnership ...
... 26 BioMosaics Inc., a cancer biomarker ... antibody product (clone 1G12) for detection of ... as an immunohistochemical test for diagnosis of ... Laboratories is a state-of-the-art reference pathology laboratory ...
... average sodium intake far exceeds recommendations, raising health risks, ... American consumes far more salt each day than is ... from the U.S. Centers for Disease Control and Prevention ... high blood pressure, blacks, and middle-age and older adults ...
... new study by researchers at the University of British Columbia ... The study, published in the Journal of Public Health ... three times more likely than those who don,t to meet ... of physical activity. , Doctoral student Ugo Lachapelle and Assoc. ...
... Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: ... completed its acquisition of Genentech pursuant to a short-form ... the Roche Group. Roche had announced earlier in the ... expired on Wednesday, March 25. In connection with the ...
Cached Medicine News:Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 3Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 2Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 3Health News:Using Too Much Salt Is Common in U.S., CDC Says 2Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:Roche Completes Acquisition of Genentech 2
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium ... a specialty biopharmaceutical company, today announced positive results ... collagenase clostridium histolyticum (or CCH) for the treatment ... cellulite. In the Phase 2a trial, all three ... high (0.84mg)) showed an improvement in the appearance ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down methamphetamine offenders and make arrests. ... Missouri blocked the sale ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits use ... of lipid antigens, which will combine ... or plasma. The particles are suspended ... eliminate non - specific reactions. Positive ...
Medicine Products: